-transparent.png){kind=logo}
In this study we evaluated the usefulness of the histocompatibility leucocyte antigen (HLA) class-I and class-II expression on renal-cell carcinoma (RCC) xenografts as predictive markers for response to cytokine therapy. Eight different RCC xenografts growing in BALBC nu/nu mice were treated with 0.5 or 5.0 ng/g recombinant human alpha- or gamma-interferon (IFN), or 500 ng/g recombinant human tumor necrosis factor (TNF). Modulation of HLA class-I, -II expression was evaluated immunohistochemically using the monoclonal antibodies (MAbs) W6.32 and B8.11.2 and at the mRNA level using the plasmids pDP001 and DR alpha 120. HLA class-I expression in all lines was upregulated by alpha- and gamma-IFN and was highest in the high-IFN-dose-treated tumors. TNF also stimulated HLA-class-I expression and up-regulated class-I expression still further when combined with IFN. Highest up-regulation of HLA-class-I in all tumors was measured in the alpha-IFN-5.0/TNF-500-ng/g-treated mice, although this was not necessarily the treatment regimen resulting in the most pronounced effect on tumor growth. Hence, maximum upregulation of class-I antigens at a given regimen was not always indicative for the highest achievable anti-tumor effect. HLA-class-II expression which was present on only 3 of the untreated tumors was up-regulated by both alpha and gamma-IFN. TNF itself did not up-regulate class-II expression but enhanced the class-II expression on the alpha-IFN-treated tumors but not on the gamma-IFN-treated tumors. Irrespective of the basic expression level, inducibility of both HLA-class-I and -class-II antigens appear to be correlated to the direct effects on growth of renal-tumor xenografts towards alpha-IFN, gamma-IFN and TNF. Modulation of HLA antigens was studied in the nude mouse, hence T-cell-mediated effector mechanisms cannot explain the good correlation between inducibility and response. Nonetheless, our studies indicate that the extent of modulation of HLA-class-I and -II can serve as predictive marker for response to cytokine therapy, which may serve as a valuable criterion for inclusion of patients in cytokine treatment regimens.
A J Beniers, and
W P Peelen, and
F M Debruyne, and
J A Schalken
February 1999,
Immunobiology,
A J Beniers, and
W P Peelen, and
F M Debruyne, and
J A Schalken
December 1988,
Cellular immunology,
A J Beniers, and
W P Peelen, and
F M Debruyne, and
J A Schalken
January 1997,
Anticancer research,
A J Beniers, and
W P Peelen, and
F M Debruyne, and
J A Schalken
September 2001,
Zhonghua zhong liu za zhi [Chinese journal of oncology],
A J Beniers, and
W P Peelen, and
F M Debruyne, and
J A Schalken
August 1999,
Journal of immunology (Baltimore, Md. : 1950),
A J Beniers, and
W P Peelen, and
F M Debruyne, and
J A Schalken
March 1995,
Journal of immunology (Baltimore, Md. : 1950),
A J Beniers, and
W P Peelen, and
F M Debruyne, and
J A Schalken
February 2001,
The American journal of pathology,
A J Beniers, and
W P Peelen, and
F M Debruyne, and
J A Schalken
March 2002,
Diabetologia,
A J Beniers, and
W P Peelen, and
F M Debruyne, and
J A Schalken
November 1994,
Journal of immunology (Baltimore, Md. : 1950),
A J Beniers, and
W P Peelen, and
F M Debruyne, and
J A Schalken
January 2008,
Revista portuguesa de pneumologia,
